Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Lancet calls on drugs industry to fund more "personalised" cancer trials

This article was originally published in Scrip

Executive Summary

In an editorial entitled, "Cancer: the revolution has begun," The Lancet has called on the pharmaceutical industry to more often fund clinical trials that stratify cancer patients by known or potential biomarkers. And while many recently completed and ongoing industry-sponsored Phase III trials have not in fact been stratified, leading cancer drug developers assert that "personalised medicine" is in fact their focus.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts